Chronic use of chloroquine disrupts the urine concentration mechanism by lowering cAMP levels in the inner medulla

American Journal of Physiology - Renal Physiology

Volumn 303, Issue 6, 2012, Pages

  von Bergen, Tobias N ^a   Blount, Mitsi A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aquaporin; AVP; cAMP; Chloroquine; Urea transporter

Indexed keywords

AQUAPORIN 2; CHLOROQUINE; CYCLIC AMP; MEMBRANE PROTEIN; SODIUM POTASSIUM CHLORIDE COTRANSPORTER; UNCLASSIFIED DRUG; UREA TRANSPORTER UT A1; UREA TRANSPORTER UT A3;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APICAL MEMBRANE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; IMMUNOHISTOCHEMISTRY; KIDNEY CONCENTRATING CAPACITY; KIDNEY MEDULLA; MALE; NONHUMAN; POLYURIA; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; URINALYSIS; URINE OSMOLALITY; URINE VOLUME; WESTERN BLOTTING;

EID: 84866418630     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00547.2011     Document Type: Article

References (38)

1. Ahmed MH, Ashton N, Balment RJ. The effect of chloroquine on renal function and vasopressin secretion: a nitric oxide-dependent effect. J Pharmacol Exp Ther 304: 156-161, 2003.
2. Ahmed MH, Ashton N, Balment RJ. Renal function in a rat model of analgesic nephropathy: effect of chloroquine. J Pharmacol Exp Ther 305: 123-130, 2003.
3. Ahmed MH, Balment RJ, Ashton N. Renal action of acute chloroquine and paracetamol administration in the anesthetized, fluid-balanced rat. J Pharmacol Exp Ther 306: 478-483, 2003.
4. Bedford JJ, Leader JP, Jing R, Walker LJ, Klein JD, Sands JM, Walker RJ. Amiloride restores renal medullary osmolytes in lithiuminduced nephrogenic diabetes insipidus. Am J Physiol Renal Physiol 294: F812-F820, 2008.
5. Bichet DG. Lithium, cyclic AMP signaling, A-kinase anchoring proteins, and aquaporin-2. J Am Soc Nephrol 17: 920-922, 2006.
6. Blount MA, Mistry AC, Frohlich O, Price SR, Chen G, Sands JM, Klein JD. Phosphorylation of UT-A1 urea transporter at serines 486 and 499 is important for vasopressin-regulated activity and membrane accumulation. Am J Physiol Renal Physiol 295: F295-F299, 2008.
7. Blount MA, Sands JM, Kent KJ, Smith TD, Price SR, Klein JD. Candesartan augments compensatory changes in medullary transport proteins in the diabetic rat kidney. Am J Physiol Renal Physiol 294: F1448-F1452, 2008.
8. Boelaert JR, Piette J, Sperber K. The potential place of chloroquine in the treatment of HIV-1-infected patients. J Clin Virol 20: 137-140, 2001.
9. Boone M, Deen PM. Physiology and pathophysiology of the vasopressinregulated renal water reabsorption. Pflügers Arch 456: 1005-1024, 2008.
10. Bruce-Chwatt LJ. Malaria and its control: present situation and future prospects. Annu Rev Public Health 8: 75-110, 1987.
11. Chen G, Huang H, Frohlich O, Yang Y, Klein JD, Price SR, Sands JM. MDM2 E3 ubiquitin ligase mediates UT-A1 urea transporter ubiquitination and degradation. Am J Physiol Renal Physiol 295: F1528-F1534, 2008.
12. Christensen BM, Zelenina M, Aperia A, Nielsen S. Localization and regulation of PKA-phosphorylated AQP2 in response to V(2)-receptor agonist/antagonist treatment. Am J Physiol Renal Physiol 278: F29-F42, 2000.
13. de Mattia F, Savelkoul PJ, Kamsteeg EJ, Konings IB, van der Sluijs P, Mallmann R, Oksche A, Deen PM. Lack of arginine vasopressininduced phosphorylation of aquaporin-2 mutant AQP2-R254L explains dominant nephrogenic diabetes insipidus. J Am Soc Nephrol 16: 2872-2880, 2005.
14. Di Fulvio M, Alvarez-Leefmans F. The NKCC and NCC Genes: An In Silico View. London, UK: Academic, 2009.
15. Ducharme J, Farinotti R. Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin Pharmacokinet 31: 257-274, 1996.
16. Eto K, Noda Y, Horikawa S, Uchida S, Sasaki S. Phosphorylation of aquaporin-2 regulates its water permeability. J Biol Chem 285: 40777-40784, 2010.
17. Ette EI, Brown-Awala EA, Essien EE. Chloroquine elimination in humans: effect of low-dose cimetidine. J Clin Pharmacol 27: 813-816, 1987.
18. Fox R. Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus 5, Suppl 1: S4-10, 1996.
19. Frisk-Holmberg M, Bergqvist Y, Termond E, Domeij-Nyberg B. The single dose kinetics of chloroquine and its major metabolite desethylchloroquine in healthy subjects. Eur J Clin Pharmacol 26: 521-530, 1984.
20. Ghigo D, Aldieri E, Todde R, Costamagna C, Garbarino G, Pescarmona G, Bosia A. Chloroquine stimulates nitric oxide synthesis in murine, porcine, and human endothelial cells. J Clin Invest 102: 595-605, 1998.
21. Hozawa S, Holtzman EJ, Ausiello DA. cAMP motifs regulating transcription in the aquaporin 2 gene. Am J Physiol Cell Physiol 270: C1695-C1702, 1996.
22. Kuhn A, Lehmann P, Ruzicka T. Cutaneous Lupus Erythematosus. New York: Springer, 2005, p. xvii.
23. Kyburz D, Brentano F, Gay S. Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling. Nat Clin Pract Rheumatol 2: 458-459, 2006.
24. Musabayane CT, Wargent ET, Balment RJ. Chloroquine inhibits arginine vasopressin production in isolated rat inner medullary segments induced cAMP collecting duct. Ren Fail 22: 27-37, 2000.
25. Musabayane CT, Windle RJ, Forsling ML, Balment RJ. Arginine vasopressin mediates the chloroquine induced increase in renal sodium excretion. Trop Med Int Health 1: 542-550, 1996.
26. Naarding MA, Baan E, Pollakis G, Paxton WA. Effect of chloroquine on reducing HIV-1 replication in vitro and the DC-SIGN mediated transfer of virus to CD4+ T-lymphocytes. Retrovirology 4: 6, 2007.
27. Nielsen S, Frokiaer J, Marples D, Kwon TH, Agre P, Knepper MA. Aquaporins in the kidney: from molecules to medicine. Physiol Rev 82: 205-244, 2002.
28. Ryan MJ. The pathophysiology of hypertension in systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol 296: R1258-R1267, 2009.
29. Sands JM. Renal urea transporters. Curr Opin Nephrol Hypertens 13: 525-532, 2004.
30. Sato T, Masuda S, Yonezawa A, Tanihara Y, Katsura T, Inui K. Transcellular transport of organic cations in double-transfected MDCK cells expressing human organic cation transporters hOCT1/hMATE1 and hOCT2/hMATE1. Biochem Pharmacol 76: 894-903, 2008.
31. Savarino A, Gennero L, Sperber K, Boelaert JR. The anti-HIV-1 activity of chloroquine. J Clin Virol 20: 131-135, 2001.
32. Seymour JF, Gagel RF. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood 82: 1383-1394, 1993.
33. Sperber K, Chiang G, Chen H, Ross W, Chusid E, Gonchar M, Chow R, Liriano O. Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. Clin Ther 19: 913-923, 1997.
34. Sperber K, Kalb TH, Stecher VJ, Banerjee R, Mayer L. Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes. AIDS Res Hum Retroviruses 9: 91-98, 1993.
35. Stewart GS, O'Brien JH, Smith CP. Ubiquitination regulates the plasma membrane expression of renal UT-A urea transporters. Am J Physiol Cell Physiol 295: C121-C129, 2008.
36. Thorogood N, Atwal S, Mills W, Jenner M, Lewis DA, Cavenagh JD, Agrawal SG. The risk of antimalarials in patients with renal failure. Postgrad Med J 83: e8, 2007.
37. Wellems Malaria TE. How chloroquine works. Nature 355: 108-109, 1992.
38. Wyatt CM, Winston JA, Malvestutto CD, Fishbein DA, Barash I, Cohen AJ, Klotman ME, Klotman PE. Chronic kidney disease in HIV infection: an urban epidemic. AIDS 21: 2101-2103, 2007.